United States Heparin Market Size (2024 - 2029)

The United States heparin market is projected to experience growth over the forecast period, driven by factors such as an increasing geriatric population and a rise in chronic diseases, including cardiovascular conditions and cancers. The market's expansion is influenced by the significant impact of the COVID-19 pandemic on surgical procedures, which has affected heparin demand. Additionally, research and development efforts by major market players aim to introduce new treatments and enhance product offerings for chronic disease management. Despite these growth drivers, the market faces challenges due to the side effects associated with heparin, which deter some patients from its use.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Anticoagulants Research United States Heparin Market Market Size

Market Size of United States Heparin Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
United States Heparin Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 1.33 Billion
Market Size (2029) USD 1.82 Billion
CAGR (2024 - 2029) 6.54 %

Major Players

United States Heparin Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

United States Heparin Market Analysis

The United States Heparin Market size is estimated at USD 1.33 billion in 2024, and is expected to reach USD 1.82 billion by 2029, growing at a CAGR of 6.54% during the forecast period (2024-2029).

The COVID-19 pandemic has significantly impacted the United States heparin market. According to an article titled, 'Response of US hospitals to elective surgical cases in the COVID-19 pandemic' published in October 2020, an early rapid decrease in United States surgical case volumes beginning mid-March 2020 was observed by the researchers. It found out that during the week of April, it was observed that there was a 71% reduction compared with the same week in 2019. Thus, the COVID-19 pandemic has affected surgical procedures tremendously which might impact the demand for heparin. Additionally, in September 2020, as a part of its 'Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)' initiative, the National Institutes of Health launched two of three adaptive Phase 3 clinical trials that will evaluate the safety and effectiveness of blood thinners (including heparin) to treat adults diagnosed with COVID-19. Positive results might prove advantages for COVID-19 patients who suffer from life-threatening blood clots.

The market is primarily driven by the rising geriatric population and an increase in incidences of chronic diseases like cardiovascular diseases and cancers. The United States has a huge burden of cancer cases. The high burden of cancer can be explained by the latest statistics provided by the International Agency for Research on Cancer, which states that in 2020, there was an estimated 2 281 658 new cancer cases diagnosed and 612 390 cancer deaths in the United States. Heparin can affect the angiogenesis, proliferation, migration and invasion of cancer cells via multiple mechanisms. The high cancer burden is expected to boost market growth.

The major market players are focusing on research and development activities to bring new and reliable treatments in the market, and they are also focusing on the product launches to effectively treat chronic diseases in the country. For instance, in March 2021, researchers from the Rhode Island Hospital started a study that determineshow quicklyheparin induced anticoagulation occurs when two different point of care activated clotting technologies (iSTATand Hemochron)are used in patients.This is an important study since promptness of heparin anticoagulation is essentialduring moststructural heart procedures.rdiology's 70th Annual Scientific Session (ACC.21).

However, side-effects of heparin are refraining the patients from its use that is hindering the market growth.

United States Heparin Industry Segmentation

As per the scope of the report, heparin is used as an anticoagulation agent which allows the body's natural clot lysis mechanisms to work normally to break down clots that have formed. The United States heparin market is segmented by Product(Unfractionated Heparin, Low Molecular Weight Heparin(LMWH) and Ultra-Low Molecular Weight Heparin(ULMWH)), Source (Bovine, Porcine), and Application (Atrial Fibrillation and Heart Attack, Stroke, Deep Vein Thrombosis (DVT) and Others). The report offers the value (in USD million) for the above segments.

By Product
Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
Ultra-Low Molecular Weight Heparin (ULMWH)
By Source
Bovine
Porcine
By Application
Atrial Fibrillation and Heart Attack
Stroke
Deep Vein Thrombosis (DVT)
Others
Need A Different Region Or Segment?
Customize Now

United States Heparin Market Size Summary

The United States heparin market is poised for significant growth, driven by an increasing geriatric population and a rise in chronic diseases such as cardiovascular conditions and cancer. The market's expansion is also influenced by the high cancer burden in the country, which necessitates the use of heparin due to its effects on cancer cell behavior. The COVID-19 pandemic initially disrupted surgical procedures, impacting heparin demand; however, it also spurred research into heparin's potential benefits for COVID-19 patients with blood clots. Major players in the market are focusing on research and development to introduce new treatments and products, aiming to address the needs of patients with chronic diseases.

Despite the promising growth prospects, the heparin market faces challenges, including side effects that deter some patients from using the drug. The prevalence of deep vein thrombosis (DVT) is expected to drive demand for heparin-based products, as a significant number of Americans are affected by this condition annually. The market is consolidated, with key players like Baxter International Inc., Pfizer Inc., and Mylan N.V. holding substantial shares. Recent developments, such as new drug applications and product launches, indicate ongoing innovation and regulatory advancements in the market, further supporting its growth trajectory over the forecast period.

Explore More

United States Heparin Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Chronic Diseases

      2. 1.2.2 Rise in Geriatric Population

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects of Heparin

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value-USD Million)

    1. 2.1 By Product

      1. 2.1.1 Unfractionated Heparin

      2. 2.1.2 Low Molecular Weight Heparin (LMWH)

      3. 2.1.3 Ultra-Low Molecular Weight Heparin (ULMWH)

    2. 2.2 By Source

      1. 2.2.1 Bovine

      2. 2.2.2 Porcine

    3. 2.3 By Application

      1. 2.3.1 Atrial Fibrillation and Heart Attack

      2. 2.3.2 Stroke

      3. 2.3.3 Deep Vein Thrombosis (DVT)

      4. 2.3.4 Others

United States Heparin Market Size FAQs

The United States Heparin Market size is expected to reach USD 1.33 billion in 2024 and grow at a CAGR of 6.54% to reach USD 1.82 billion by 2029.

In 2024, the United States Heparin Market size is expected to reach USD 1.33 billion.

United States Heparin Market Report Snapshots

United States Heparin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)